Drug Channels

MARCH 14, 2022

Click here to read my review of Dr. Gottlieb’s excellent book. This book will be one of the bibles of this era.” — Andy Slavitt, former White House senior advisor for the COVID-19 response Have a question for Dr. Gottlieb and Dr. Fein to review during their interactive fireside chat? Send it to connect@asembiasummit.com.

Specialty Pharmacies 74

Specialty Pharmacies Pharmacy FDA Science 74

Broad Institute

NOVEMBER 14, 2023

He’s been involved in every stage of the process, including managing the 10 pharmaceutical companies and two nonprofit organizations contributing to the database, designing experiments, and creating data analysis pipelines. Then I read a book about Albert Einstein and the theory of relativity.

Science 115

Science Pharmaceutical Companies Pharmaceuticals Engineering 115

Drug Patent Watch

FEBRUARY 15, 2024

Designed for excipient manufacturers seeking lucrative opportunities in the pharmaceutical industry, these reports offer invaluable… The post Drug Excipient Business Development Reports now Available on Amazon appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 105

Drugs Pharmaceuticals 105

ACTO

NOVEMBER 15, 2023

I have always been a reader… I love books, magazines, newspapers - anything I can get my hands on. If you wanted a specific book, you would go to the librarian and ask for it. With bated breath, you would wait to see if the librarian found a card for the book you wanted. Can you imagine?? Can you imagine??

Science 52

Science Pharmaceuticals Marketing 52

The Pharma Data

DECEMBER 1, 2020

01, 2020 (GLOBE NEWSWIRE) — Allena Pharmaceuticals, Inc. is acting as the sole book-running manager for the offering. About Allena Pharmaceuticals Allena Pharmaceuticals, Inc. NEWTON, Mass., per share, less underwriting discounts and commissions. Wainwright & Co.

Pharmaceuticals 52

Pharmaceuticals Clinical Trials Trials Clinical Development 52

FDA Law Blog: Biosimilars

JULY 24, 2024

Each fall, leading pharmaceutical patent litigators for brand-name and generic drug companies gather at the Paragraph IV Disputes Master Symposium in Chicago to receive up-to-the-minute information on the latest developments affecting Hatch-Waxman litigation and participate in significant peer-to-peer networking opportunities. s Kurt R.

Small Molecule 52

Small Molecule Clinical Trials FDA Pharmaceuticals 52

The Pharma Data

OCTOBER 15, 2020

BofA Securities, Jefferies and Raymond James are acting as joint book-running managers for the offering. About Tarsus Pharmaceuticals, Inc. Tarsus Pharmaceuticals, Inc. IRVINE, Calif., per share, for gross proceeds of $88.0 million, before underwriting discounts, commissions, and offering expenses payable by Tarsus.

Pharmaceuticals 40

Pharmaceuticals Marketing Treatment Disease 40

The Pharma Data

DECEMBER 14, 2020

Morgan, SVB Leerink and Evercore ISI are acting as joint book-running managers for the offering. About Mirum Pharmaceuticals, Inc. Mirum Pharmaceuticals, Inc. The offering is expected to close on December 17, 2020, subject to satisfaction of customary closing conditions. Wainwright & Co.

Pharmaceuticals 40

Pharmaceuticals Treatment Marketing Therapies 40

FDA Law Blog: Biosimilars

SEPTEMBER 23, 2024

For the 40th anniversary of the Orange Book (and the quasi-35th anniversary of Hatch-Waxman), we put together a public Orange Book Archive (and it has become one of the more popular stops on the FDA Law Blog). For the 25th and 30th anniversaries, we held trivia contests ( here and here ).

FDA 59

FDA Drugs International Pharmaceuticals 59

Drug Channels

SEPTEMBER 23, 2024

View the Complete Agenda Book Your Place The complex components of gross-to-net management requires cross-functional collaboration in order to effectively develop sound accrual estimates, proper forecasting, optimized pricing and contracting models and accurate financial reporting, all with minimal disruption to market access strategies.

Compliance 52

Compliance Pharmaceuticals Marketing Government 52

The Pharma Data

OCTOBER 23, 2020

Dr. Elmaleh is a biotechnology entrepreneur, pharmaceutical chemist and molecular imaging expert with more than four decades of innovation in healthcare research. Dr. Elmaleh has contributed to more than 130 book chapters, scientific papers, and professional journal articles. and Pure Tech Health.

Organic Chemistry 52

Organic Chemistry Clinical Trials Science Pharmaceuticals 52

Drug Target Review

JUNE 12, 2023

Since 2012, he has published over 150 peer-reviewed research papers, and 2 books including “The Ageless Generation: How Biomedical Advances Will Transform the Global Economy” (Macmillan, 2013). He is an adjunct professor of artificial intelligence at the Buck Institute for Research on Aging.

Metabolic Stability 92

Metabolic Stability Clinical Trials Small Molecule Pharmacokinetics 92

The Pharma Data

NOVEMBER 29, 2020

Prior to joining Gannex, Dr. Palmer was Head of Liver Disease Clinical Development at Takeda Pharmaceuticals. She has also held senior leadership positions at Shire Pharmaceuticals and Kadmon Corporation, where she was in charge of the global development of NASH and other liver disease programs.

Clinical Development 40

Clinical Development Disease Clinical Trials Therapies 40

The ChEMBL-og

MARCH 1, 2023

New Deposited Datasets CHEMBL5058649 - Data for DCP probe BAY 1816032 * CHEMBL5058643 - Data for DCP probe BI-2081 * CHEMBL5058646 - Data for DCP probe CCT369260 * CHEMBL5058644 - Data for DCP probe JNJ-39758979 * CHEMBL5058645 - Data for DCP probe JNJ-6204 * CHEMBL5058647 - Data for DCP probe JNJ-9350 * CHEMBL5058648 - Data for DCP probe SAFit2 * (..)

International 52

International Pharmaceuticals Production Drugs 52

Altus Drug Development

JUNE 30, 2022

A focus on customers has always been one of the main pillars of the pharmaceutical industry. While this strategy is widely adopted by modern pharmaceutical companies, in recent years, its effectiveness has begun to wane. The onset of the covid-19 pandemic has caused considerable strain on the pharmaceutical industry as a whole.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceuticals Treatment Production 52

The Pharma Data

DECEMBER 8, 2020

LLC, Citigroup and Cowen are acting as joint book-running managers for the offering. About Syndax Pharmaceuticals, Inc. Syndax Pharmaceuticals is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. SOURCE Syndax Pharmaceuticals, Inc.

Pharmaceuticals 52

Pharmaceuticals Therapies Marketing 52

Drug Target Review

OCTOBER 14, 2024

who shared his thoughts on the challenges faced by biotech companies in drug discovery, highlighting the critical role of data and technology in overcoming inefficiencies in the pharmaceutical industry. He has published several papers and two books and has twelve issued patents. We interviewed Dr Neil Wilkie, CEO of Mironid Ltd.,

Science 52

Science Pharmaceutical Companies Drug Development Pharmaceuticals 52

Alta Sciences

DECEMBER 14, 2023

BOOK A VISIT You may also be interested in the following webpages:​​​ Clinical Research Services Pharmaceutical CDMO and Contract Manufacturing Services DID YOU KNOW? Our CDMO team offers formulation development and manufacturing of your API, from discovery through commercialization.

Compounding Pharmacies 40

Compounding Pharmacies Pharmacy Clinical Pharmacology Clinical Supply 40

The Pharma Data

DECEMBER 2, 2020

are acting as joint book-running managers. Twist may also use a portion of the net proceeds to in-license, acquire or invest in complementary businesses or products. Morgan Securities LLC, Goldman Sachs & Co. LLC, Cowen and Company, LLC and Evercore Group L.L.C. Baird & Co. Incorporated is acting as lead manager.

DNA 52

DNA Licensing Licensing Pharmaceuticals 52

Sygnature Discovery

OCTOBER 9, 2024

About Reaxys Reaxys is a chemistry research and education solution from Elsevier providing chemical substance, properties, reaction and medicinal chemistry information for both bench chemistry and machine learning methods used in drug discovery and chemical/pharmaceutical R&D.

Science 52

Science Disease Research Pharmaceuticals 52

Drug Target Review

OCTOBER 24, 2024

He has published several papers and two books and has twelve issued patents. As a member of leadership teams, Janette has broad experience in developing company and product R&D strategy, leading research programs and has published journal articles, book chapters and is an inventor on granted patents.

Cell Based Assays 52

Cell Based Assays Science Disease Doctors 52

The Pharma Data

JANUARY 19, 2021

–( BUSINESS WIRE )– Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, announced today that it has priced an underwritten public offering of 5,400,000 shares of common stock at a public offering price of $14.00 About Syros Pharmaceuticals. 20, 2021 03:41 UTC.

Small Molecule 52

Small Molecule Clinical Trials Pharmaceuticals Virus 52

The Pharma Data

JANUARY 12, 2021

From 2010 to 2020, Dr Graham was VP of Strategic Program Direction, Immunology and Inflammation at Regeneron Pharmaceuticals, Inc., He is the author of five chapters and books and more than 140 peer-reviewed journal articles. Multiple IND’s, NDA/BLA filings and/or defense and multiple successful launches. Dr. Graham earned an M.D.,

Science 52

Science Clinical Development Disease Production 52

The Pharma Data

JANUARY 13, 2021

Nasdaq: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders and diseases, today announced that it has priced an underwritten public offering of 5,000,000 shares of its common stock at a price to the public of $2.50 is acting as sole book-running manager for the offering.

Pharmaceutical Companies 40

Pharmaceutical Companies FDA Approval Clinical Trials Pharmaceuticals 40

The Pharma Data

NOVEMBER 19, 2020

Neurotrope and Metuchen previously announced their intent to merge in an all-stock transaction resulting in the formation of a holding company to be named Petros Pharmaceuticals, Inc. (“Petros”), which expects to trade on the Nasdaq Capital Market under the symbol “PTPI” following the closing of the merger.

Pharmaceuticals 52

Pharmaceuticals Marketing Disease Clinical Trials 52

The Pharma Data

JANUARY 19, 2021

is acting as the sole book-running manager for the offering. The Company’s business model is to in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development and/or commercialization. Wainwright & Co.

Clinical Trials 52

Clinical Trials Trials Clinical Development Pharmaceutical Companies 52

Vial

FEBRUARY 19, 2024

Explore the groundbreaking VersAptx bioconjugation platform, designed to elevate cancer therapies and uncover the delicate balance between clinical excellence and commercial viability in the dynamic landscape of pharmaceuticals. We always try to stick with The Four Agreements. You speak impeccably. Don’t make any assumptions.

Small Molecule 52

Small Molecule Therapies Treatment Science 52

Practical Cheminformatics

AUGUST 3, 2023

I co-wrote a book with several of them and greatly respect their scientific abilities and accomplishments. Most pharmaceutical compounds tend to have solubilities somewhere between 1 and 500 µM. Many have suggested that pharmaceutical companies should open more of their data to the community.

Drugs 84

Drugs Biochemical Assays Metabolic Stability Screening Hits 84

Elrig

SEPTEMBER 19, 2023

The two-day event covers a range of cutting-edge topics in the field — including cellular technologies for drug discovery, augmenting R&D with AI, and translating ideas into therapies — delivered by a line-up of expert speakers from the pharmaceutical and biotech industries.

Drugs 59

Drugs Disease Therapies Research 59

The Pharma Data

DECEMBER 14, 2020

The Company anticipates using net proceeds from the offering to fund the continued development of ublituximab and umbralisib, the potential in-license, acquisition, development and commercialization of other pharmaceutical products, and for general corporate purposes. are acting as joint book-running managers for the proposed offering.

Clinical Trials 40

Clinical Trials Clinical Development Production Trials 40

Agency IQ

JULY 8, 2024

and the E.C.

FDA 40

FDA Science Regulations Production 40

Codon

APRIL 9, 2024

When her father gave Tu the name “Youyou,” he started with characters from the Chinese classic Book of Odes: “The deer bleat: ‘yōu yōu’ while eating wild ‘hāo’” (呦呦鹿鸣，食野之蒿). falciparum.

Drugs 140

Drugs Science Research Doctors 140

LifeSciVC

APRIL 27, 2023

Then came 2021, the most consequential, and tumultuous, year in the Book of Nimbus thus far. Our small team was able to support multiple major pharmaceutical companies plowing through diligence, not just withstanding the onslaught but in fact delivering a data package of Phase 3-ready quality.

Small Molecule 40

Small Molecule Computational Chemistry Engineering Clinical Development 40

The Pharma Data

JANUARY 20, 2021

His publication list includes more than 475 articles and 7 book chapters. Dr. Wells has worked extensively with governments and non-government research organizations, as well as private pharmaceutical and biotechnology companies. Dr. Wells is the author or co-author of over 400 published articles.

Hospitals 52

Hospitals Trials International Clinical Trials 52

The Pharma Data

JANUARY 31, 2021

based database, iSpecimen offers single-source access to biospecimens and biospecimen datasets to researchers within biotech, pharmaceutical and diagnostic companies, as well as to healthcare providers. We’re trying to do what Amazon did in the early days if I’m a book buyer. Leveraging an extensive, mostly-U.S.

Research 52

Research Clinical Trials Trials Science 52

The Pharma Data

MAY 15, 2021

Let me tell you my story… I lived a full, busy life working as a researcher in a pharmaceutical company, taught aerobics twice weekly in the evenings, volunteered at a local shelter during the weekend, and also did all the things that mothers do (2 children). This book will guide you step-by-step, and it is extremely easy to follow.

Doctors 52

Doctors Production Therapies Treatment 52

Agency IQ

OCTOBER 6, 2023

CDER is the FDA office in charge of reviewing pharmaceuticals and therapeutic biologics. All products are received in one of two forms: A New Drug Application (or NDA, for pharmaceuticals) or a Biologics License Application (BLA, for biologics). FY 2023 saw the largest number of novel biologic products approved in a single fiscal year.

FDA 52

FDA Biosimilars Science Drugs 52